Want to join the conversation?
On March 2, 2016, $A acquired a 48% ownership stake in privately held Lasergen for $80MM in cash. As part of the agreement, the two companies will collaborate on a next-generation sequencing solutions workflow for clinical applications. The company has the option to acquire the remaining shares of Lasergen until March 2, 2018, for $105MM.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.